Australian Pediatric Autism RCT Reports Eight-Week Symptom Improvements with Low-THC NTI164
An Australian double-blind placebo-controlled Phase II/III NTI164 trial randomized 61 children and adolescents, with 54 completing eight weeks. Symptoms improved and no serious adverse events were reported. Small size, one site, short duration and commercial funding limit conclusions about general efficacy and long-term safety.
For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.
Source
neurotherapeuticsjournal.org
CannabisInsight selects and summarizes news from external sources. Copyright in the original articles remains with the respective publishers or institutions. Follow the source links for full reporting and context.
Original Link
https://www.neurotherapeuticsjournal.org/article/S1878-7479%2826%2900203-5/fulltext